[Bone replacement using beta-tricalcium phosphate--results of experimental studies and initial clinical case examples].
Beta-Tricalcium phosphate granulates (Ceros 82) implanted in femurs of the rat led to osteoconduction already one week after implantation. Compared to the problems of autologous implants, TCP presents many advantages: No operation on the donor site, no limitation of quantity, clinically negligible resorption, immediate osteoconduction. The results on femoral defects of 26 rats filled up by beta-TCP and our first clinical experiences on juvenile bone cysts are presented.
D000818:Animals; D001845:Bone Cysts / Q000601:surgery*; D001861:Bone Regeneration / Q000187:drug effects; D002111:Calcaneus / Q000601:surgery; D002130:Calcium Phosphates; D002648:Child; D004338:Drug Combinations / Q000008:administration & dosage; D005176:Factor XIII / Q000008:administration & dosage; D005269:Femur / Q000601:surgery; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000008:administration & dosage; D006801:Humans; D008297:Male; D019736:Prostheses and Implants; D051381:Rats; D011919:Rats, Inbred Strains; D013917:Thrombin / Q000008:administration & dosage
D002130:Calcium Phosphates; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; C485817:beta-tricalcium phosphate; D005340:Fibrinogen; D005176:Factor XIII; D013917:Thrombin; C018392:tricalcium phosphate
Knochenersatzplastiken mit Beta-Tricalciumphosphat--Resultate experimenteller Studien und erste klinische Fallbeispiele.